STOCK TITAN

Adial Pharmaceuticals, Inc - ADIL STOCK NEWS

Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company dedicated to developing treatments for addiction and related disorders. The company's primary focus is on creating personalized therapies that address the unique needs of individuals suffering from substance abuse. Adial's flagship product, AD04, is a serotonin-3 receptor antagonist aimed at treating Alcohol Use Disorder (AUD) in patients with specific genetic profiles. AD04 has shown promise in reducing excessive drinking in heavy drinking patients and has been investigated in the company's ONWARD™ pivotal Phase 3 clinical trial. The active ingredient in AD04 is ondansetron, which is commonly used to prevent nausea and vomiting, and now brings potential benefits in addiction treatment.

Adial leverages its expertise in pharmacogenomics to develop therapies that are tailored to the genetic makeup of patients. This approach has the potential to revolutionize the treatment of addiction by providing more effective and safer treatment options. The company recently regained compliance with Nasdaq's listing requirements by maintaining a stockholders' equity of at least $2.5 million. Adial has also been active in forming strategic partnerships, including an agreement with Adovate, LLC, which could yield up to $83 million in milestone payments and commercial royalties.

Adial's intellectual property portfolio is robust, with multiple patents protecting the combination of its genetic diagnostics and AD04 for the treatment of AUD, Opioid Use Disorder (OUD), and other dependencies. The company's recent awards include the 2023 Best Practices Technology Innovation Leadership Award from Frost & Sullivan. Financially, Adial is in a stable position, with cash and cash equivalents allowing it to fund operations into the first quarter of 2025. The company's research and development expenses have been judiciously managed, ensuring that resources are effectively utilized.

Recent studies have underscored the safety and efficacy of AD04, highlighting its favorable liver safety profile compared to placebo and its potential to treat other addictive disorders like gambling and obesity. Adial has initiated new activities related to its clinical development plan, including two parallel Phase 3 clinical trials of AD04 to support its approval in the shortest timeframe possible. The company is also engaging with the FDA to refine its study designs and enhance the likelihood of regulatory success.

Adial Pharmaceuticals continues to make significant strides in its mission to develop innovative solutions for addiction treatment, offering hope to millions affected by these disorders worldwide.

Rhea-AI Summary
Adial Pharmaceuticals, Inc. announces the immediate exercise of warrants, raising $3.5 million. H.C. Wainwright & Co. acts as the exclusive placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.64%
Tags
none
-
Rhea-AI Summary
Adial Pharmaceuticals strengthens its patent portfolio with a new patent covering AD04's ability to target the serotonin transporter gene for treating opioid use disorder. The patent was issued by the United States Patent and Trademark Office, highlighting the company's commitment to developing therapies for addiction and related disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
86.21%
Tags
none
-
Rhea-AI Summary
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announces participation in Winter Wrap-Up MicroCap Rodeo Conference. CEO Cary Claiborne to present on February 20, 2024, and host one-on-one meetings with investors. Register at webcaster4.com and MicroCap Rodeo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
conferences
Rhea-AI Summary
Adial Pharmaceuticals expands its patent estate to cover a unique genetic diagnostic approach for treating alcohol and drug dependencies. The Company's lead drug, AD04, shows promising results in specific genotype patients, potentially revolutionizing addiction treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.85%
Tags
none
-
Rhea-AI Summary
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) announced the appointment of Tony Goodman as Chief Operating Officer. Goodman will oversee strategic growth initiatives, clinical development, and commercial planning for AD04, as well as business development initiatives focused on partnership opportunities in the addiction treatment space. With over 23 years of experience in the pharmaceutical and biotech industries, Goodman's appointment signifies a pivotal time for the company as it prepares to advance the AD04 clinical program and potential commercialization for the treatment of alcohol use disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
management
-
Rhea-AI Summary
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) received a final development cost reimbursement payment of $350,000 from Adovate, LLC. The company is eligible for up to $83 million in total consideration, including development and approval milestones, commercial milestones, and a low, single-digit royalty. Additionally, Adial acquired a 15% equity stake in Adovate and has anti-dilution protection. This agreement is a significant milestone for Adial's business development and potential future revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
none
Rhea-AI Summary
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) has regained compliance with Nasdaq Listing Rule 5550(b)(1) requiring listed companies to maintain stockholders' equity of at least $2,500,000. If the Company does not evidence compliance in its next periodic report, it may be subject to delisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
none
-
Rhea-AI Summary
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) reported receiving Frost & Sullivan’s 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award, closed a $4 million private placement, and extended its cash runway into Q4 2024. The company is advancing discussions with potential strategic partners and has made steady progress throughout the third quarter of 2023. Adial is pursuing a highly focused regulatory strategy and is finalizing its clinical development plan for AD04, aiming for approval in the U.S. and EU. The company is also under confidentiality agreements and in discussions with companies interested in supporting the development and commercial launch of AD04. Adial has improved its balance sheet as a result of the recent private placement and received the 2023 Best Practices Technology Innovation Leadership Award in the North American precision medicine for addiction disorders industry by Frost & Sullivan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
-
Rhea-AI Summary
Adial Pharmaceuticals, Inc. will be presenting at The Annual International Society of Addiction Medicine Conference. The presentation will highlight the effects of AD04, the Company's therapeutic agent for the treatment of Alcohol Use Disorder (AUD). The phase 3 clinical trial results support the use of AD04 as a precision medicine to treat AUD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
Rhea-AI Summary
Adial Pharmaceuticals recently hosted a webinar with addiction experts to discuss the need for non-abstinence-based therapies for alcohol use disorder (AUD). Current medications are not widely prescribed or utilized, and adherence is a concern. The experts believe that non-abstinence-based treatments can reduce barriers to treatment and improve patient engagement. They emphasize that reductions in excessive drinking, even without complete abstinence, can have a major public health impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none

FAQ

What is the current stock price of Adial Pharmaceuticals (ADIL)?

The current stock price of Adial Pharmaceuticals (ADIL) is $1.01 as of November 22, 2024.

What is the market cap of Adial Pharmaceuticals (ADIL)?

The market cap of Adial Pharmaceuticals (ADIL) is approximately 6.4M.

What is Adial Pharmaceuticals' main focus?

Adial Pharmaceuticals focuses on developing personalized treatments for addiction and related disorders, leveraging pharmacogenomics to tailor therapies to individual genetic profiles.

What is AD04?

AD04 is Adial's lead investigational new drug, a serotonin-3 receptor antagonist used to treat Alcohol Use Disorder (AUD) in heavy drinking patients with specific genetic profiles.

What recent achievements has Adial Pharmaceuticals made?

Adial has regained compliance with Nasdaq's listing requirements, formed a strategic partnership with Adovate, LLC, and received multiple patents protecting its genetic diagnostics and AD04.

How is AD04 different from other treatments for AUD?

AD04 is genetically targeted, meaning it is tailored to patients with specific genetic profiles, enhancing its effectiveness and safety compared to conventional treatments.

What financial position is Adial Pharmaceuticals currently in?

Adial is financially stable, with cash and cash equivalents allowing it to fund operations into the first quarter of 2025. The company is also managing its research and development expenses efficiently.

What are the potential applications of AD04 beyond AUD?

AD04 has shown potential to treat other addictive disorders such as Opioid Use Disorder (OUD), gambling, and obesity.

How has Adial Pharmaceuticals engaged with regulatory agencies?

Adial has received favorable feedback from both US and European regulators, helping to refine its clinical development plan and enhance the likelihood of regulatory success for AD04.

What recent studies have been conducted on AD04?

Recent studies have highlighted AD04's safety profile, particularly its minimal impact on liver function, and its efficacy in reducing heavy drinking in patients with specific genetic markers.

What strategic partnerships has Adial Pharmaceuticals formed?

Adial has partnered with Adovate, LLC, securing potential milestone payments and royalties, and is in discussions with other potential strategic partners to support the development and launch of AD04.

What are the next steps for Adial's clinical development plan?

Adial plans to conduct two parallel Phase 3 clinical trials of AD04 and engage with the FDA to refine study designs, aiming for regulatory approval and commercialization.

Adial Pharmaceuticals, Inc

Nasdaq:ADIL

ADIL Rankings

ADIL Stock Data

6.41M
6.29M
1.8%
3.03%
1.23%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHARLOTTESVILLE